Bionime will offer innovative GE-branded clinical and home-based patient care products for the rapidly growing global diabetes population
Albany, NY and Milwaukee, WI --17 January 2012-- GE (NYSE: GE) today announced it has entered into a new worldwide licensing agreement with Bionime, a global leader in biotechnology medical testing, to provide new GE-branded solutions for the diabetes market.